Efficacy evaluation of serum galectin-3 in hypertension complicated with diastolic dysfunction

Dong,Tianwei; Li,Hongbin; Wang,Shuang; Chen,Weida

doi:10.3892/etm.2019.8215

Efficacy evaluation of serum galectin-3 in hypertension complicated with diastolic dysfunction

Authors:
- Tianwei Dong
- Hongbin Li
- Shuang Wang
- Weida Chen
View Affiliations

Affiliations: Department of Cardiovascular Medicine, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154002, P.R. China, Department of Neurosurgery, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154002, P.R. China
Published online on: November 18, 2019 https://doi.org/10.3892/etm.2019.8215
Pages: 147-152
Copyright: © Dong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Serum galectin-3 (Gal-3) in patients with hypertension complicated with diastolic dysfunction and its predictive value for efficacy were investigated. One hundred patients with hypertension complicated with diastolic dysfunction admitted to the First Affiliated Hospital of Jiamusi University from June 2017 to December 2018 were enrolled as group A, symptomatically treated with conventional drugs. Further 80 individuals undergoing physical examination during the same period were enrolled as group B. Patients in the two groups were subjected to echocardiography to observe mitral valve early peak flow velocity (EPFV), atrial peak flow velocity (APFV), maximum flow velocity ratio of early to atrial diastole (EPFV/APFV) and peak mitral annulus velocity (E/E'). Enzyme-linked immunosorbent assay (ELISA) was used to detect serum Gal-3 concentration. According to efficacy after treatment, patients in group A were divided into the effective group (71 patients) and the invalid group (29 patients). Gal-3 concentration in group A was significantly higher than that in group B (P<0.05). After treatment, the concentration in group A was significantly lower than that before treatment (P<0.05), but significantly higher than that in group B (P<0.05). Gal-3 concentration was significantly higher in patients with cardiac function grades II, III and IV than that in patients with grade I (P<0.05). According to Spearman's test, Gal-3 concentration was positively correlated with cardiac function grading (r=0.569, P<0.001). Compared with before treatment in group A, patients after treatment had significantly higher EPFV and EPFV/APFV (P<0.05), but significantly lower APFV and E/E' (P<0.05). Before treatment, Gal-3 concentration in the effective group was significantly lower than that in the invalid group (P<0.05). According to the receiver operating characteristic (ROC) curve, the area under curve (AUC) of Gal-3 concentration for evaluating efficacy was 0.792, the sensitivity was 73.24%, and the specificity was 79.31%. In conclusion, Gal-3 may be involved in the development and progression of hypertension complicated with diastolic dysfunction. Its concentration increases with the rise of cardiac function grading but significantly decreases after treatment. Therefore, Gal-3 concentration before treatment can be used as a potential predictor of efficacy.

View Figures

View References

1	Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, et al CHEP Guidelines Task Force, : Hypertension Canada's 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 32:569–588. 2016. View Article : Google Scholar : PubMed/NCBI
2	Oluboka OJ, Katzman MA, Habert J, McIntosh D, MacQueen GM, Milev RV, McIntyre RS and Blier P: Functional recovery in major depressive disorder: Providing early optimal treatment for the individual patient. Int J Neuropsychopharmacol. 21:128–144. 2018. View Article : Google Scholar : PubMed/NCBI
3	Soullier C, Niamkey JT, Ricci JE, Messner-Pellenc P, Brunet X and Schuster I: Hypertensive patients with left ventricular hypertrophy have global left atrial dysfunction and impaired atrio-ventricular coupling. J Hypertens. 34:1615–1620. 2016. View Article : Google Scholar : PubMed/NCBI
4	Ravassa S, López B, Querejeta R, Echegaray K, San José G, Moreno MU, Beaumont FJ, González A and Díez J: Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome. J Hypertens. 35:853–861. 2017. View Article : Google Scholar : PubMed/NCBI
5	Nazário Leão R and Marques da Silva P: Diastolic dysfunction in hypertension. Hipertens Riesgo Vasc. 34:128–139. 2017. View Article : Google Scholar : PubMed/NCBI
6	Ginelli P and Bella JN: Treatment of diastolic dysfunction in hypertension. Nutr Metab Cardiovasc Dis. 22:613–618. 2012. View Article : Google Scholar : PubMed/NCBI
7	Nadruz W, Shah AM and Solomon SD: Diastolic dysfunction and hypertension. Med Clin North Am. 101:7–17. 2017. View Article : Google Scholar : PubMed/NCBI
8	Zhang Y, Sun N, Jiang X and Xi Y: Comparative efficacy of β-blockers on mortality and cardiovascular outcomes in patients with hypertension: A systematic review and network meta-analysis. J Am Soc Hypertens. 11:394–401. 2017. View Article : Google Scholar : PubMed/NCBI
9	Wallentin F, Wettermark B and Kahan T: Drug treatment of hypertension in Sweden in relation to sex, age, and comorbidity. J Clin Hypertens (Greenwich). 20:106–114. 2018. View Article : Google Scholar : PubMed/NCBI
10	Anyfanti P, Gkaliagkousi E, Gavriilaki E, Triantafyllou A, Dolgyras P, Galanopoulou V, Aslanidis S and Douma S: Association of galectin-3 with markers of myocardial function, atherosclerosis, and vascular fibrosis in patients with rheumatoid arthritis. Clin Cardiol. 42:62–68. 2019. View Article : Google Scholar : PubMed/NCBI
11	González GE, Rhaleb NE, D'Ambrosio MA, Nakagawa P, Liao TD, Peterson EL, Leung P, Dai X, Janic B, Liu YH, et al: Cardiac-deleterious role of galectin-3 in chronic angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol. 311:H1287–H1296. 2016. View Article : Google Scholar : PubMed/NCBI
12	Jagodzinski A, Havulinna AS, Appelbaum S, Zeller T, Jousilahti P, Skytte-Johanssen S, Hughes MF, Blankenberg S and Salomaa V: Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort. Int J Cardiol. 192:33–39. 2015. View Article : Google Scholar : PubMed/NCBI
13	Meijers WC, van der Velde AR and de Boer RA: ST2 and galectin-3: Ready for prime time? EJIFCC. 27:238–252. 2016.PubMed/NCBI
14	Ghorpade AG, Shrivastava SR, Kar SS, Sarkar S, Majgi SM and Roy G: Estimation of the cardiovascular risk using World Health Organization/International Society of Hypertension (WHO/ISH) risk prediction charts in a rural population of South India. Int J Health Policy Manag. 4:531–536. 2015. View Article : Google Scholar : PubMed/NCBI
15	Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, Shao L, Tian Y, Dong Y, Zheng C, et al China hypertension survey investigators, : Status of hypertension in China: Results from the China hypertension survey, 2012–2015. Circulation. 137:2344–2356. 2018. View Article : Google Scholar : PubMed/NCBI
16	Bansal M, Kasliwal RR and Trehan N: Relationship between different cardiovascular risk scores and measures of subclinical atherosclerosis in an Indian population. Indian Heart J. 67:332–340. 2015. View Article : Google Scholar : PubMed/NCBI
17	Deckx S, Heggermont W, Carai P, Rienks M, Dresselaers T, Himmelreich U, van Leeuwen R, Lommen W, van der Velden J, Gonzalez A, et al: Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation. Matrix Biol. 66:110–124. 2018. View Article : Google Scholar : PubMed/NCBI
18	Maiolino G, Rossitto G, Pedon L, Cesari M, Frigo AC, Azzolini M, Plebani M and Rossi GP: Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 35:725–732. 2015. View Article : Google Scholar : PubMed/NCBI
19	Calvier L, Legchenko E, Grimm L, Sallmon H, Hatch A, Plouffe BD, Schroeder C, Bauersachs J, Murthy SK and Hansmann G: Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension. Heart. 102:390–396. 2016. View Article : Google Scholar : PubMed/NCBI
20	Singh T, Pilania M, Jat GS and Kumar R: Ambiguity about selection of cardiovascular risk stratification tools: Evidence from a North Indian rural population. Indian J Community Med. 43:170–174. 2018.PubMed/NCBI
21	Wu H, Chen L, Xie J, Li R, Li GN, Chen QH, Zhang XL, Kang LN and Xu B: Periostin expression induced by oxidative stress contributes to myocardial fibrosis in a rat model of high salt-induced hypertension. Mol Med Rep. 14:776–782. 2016. View Article : Google Scholar : PubMed/NCBI
22	Hogas S, Bilha SC, Branisteanu D, Hogas M, Gaipov A, Kanbay M and Covic A: Potential novel biomarkers of cardiovascular dysfunction and disease: Cardiotrophin-1, adipokines and galectin-3. Arch Med Sci. 13:897–913. 2017. View Article : Google Scholar : PubMed/NCBI
23	Gorostidi M and de la Sierra A: Combination therapy in hypertension. Adv Ther. 30:320–336. 2013. View Article : Google Scholar : PubMed/NCBI
24	Shah SJ and Stafford RS: Current trends of hypertension treatment in the United States. Am J Hypertens. 30:1008–1014. 2017. View Article : Google Scholar : PubMed/NCBI
25	Taddei S: Combination therapy in hypertension: What are the best options according to clinical pharmacology principles and controlled clinical trial evidence? Am J Cardiovasc Drugs. 15:185–194. 2015. View Article : Google Scholar : PubMed/NCBI
26	Gradman AH: Strategies for combination therapy in hypertension. Curr Opin Nephrol Hypertens. 21:486–491. 2012. View Article : Google Scholar : PubMed/NCBI
27	Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, Sádaba JR, Zannad F, Rossignol P and López-Andrés N: The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail. 3:59–67. 2015. View Article : Google Scholar : PubMed/NCBI
28	Vergaro G, Prud'homme M, Fazal L, Merval R, Passino C, Emdin M, Samuel JL, Cohen Solal A and Delcayre C: Inhibition of galectin-3 pathway prevents isoproterenol-induced left ventricular dysfunction and fibrosis in mice. Hypertension. 67:606–612. 2016. View Article : Google Scholar : PubMed/NCBI